MZL and ASCT

The aim of this study was to determine the outcome in patients with either relapsed or refractory marginal zone lymphoma (MZL) undergoing autologous stem cell transplantation.

Results were presented at the 2014 American Society of Hematology annual meeting. Patients (n = 111) had nodal, extranodal (MALT) MZL, 55 patients had nodal MZL and 33 patients had splenic MZL. Five-year event-free survival (EFS) and overall survival (OS) were 53% (95% CI 45-61%) and 73% (95% CI 65-79%), respectively.

Multivariate analysis showed that those older than 65 years had both a shorter EFS and OS (HR = 8.6, 95% CI 2.8-26.2, p<0.001; HR = 5.2, 95% CI 1.9-14, p = 0.001, respectively). As well, MZL predicted a shorter OS than MALT (HR = 3.2, 95% CI 1.2-8.7, p = 0.023).

Click here for the full article.

 

Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe

WEIGH-IN WEDNESDAY

Are you aware cancer patients can experience chemo brain without ever receiving chemotherapy?

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.